PharmAthene Presents Data For SparVax(TM), A Novel Vaccine For The Prevention And Treatment Of Anthrax Infection

PharmAthene Presents Data For SparVax(TM), A Novel Vaccine For The Prevention And Treatment Of Anthrax Infection
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. The conference is sponsored by the National Foundation of Infectious Diseases. David P.

Asthma Sufferers Should Be Cautious Of Swine Flu

As news of the swine flu situation develops, it is important for those with asthma or other respiratory conditions to be aware of the basic facts about influenza and how it is spread, according to the American Academy of Allergy, Asthma & Immunology. "The typical influenza vaccine does not provide immunity to swine flu," said Executive Vice President Thomas B. Casale, MD, FAAAAI. "As with other influenza viruses, this virus typically attacks the respiratory tract. More at...

Phase II Study Suggests Future For Radioembolisation In Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase II Study Suggests Future For Radioembolisation In Patients With Advanced Hepatocellular Carcinoma (HCC)
Radioembolisation with Yttrium-90 (Y-90) glass microspheres is a safe and effective treatment for patients with advanced HCC ± portal vein thrombosis, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. According to the researchers, these findings create the foundation for a trial comparing and combining radioembolisation with multi-targeted kinase inhibitor, sorafenib.